These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36672491)

  • 41. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
    Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.
    AlRuthia Y; Alharbi O; Aljebreen AM; Azzam NA; Almadi MA; Bahari OH; Almalki KA; Atham AT; Alanazi AS; Saeed M; HajkhderMullaissa B; Alsenaidy M; Balkhi B
    Cost Eff Resour Alloc; 2019; 17():25. PubMed ID: 31827409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease.
    Yamamoto-Furusho JK; Bosques-Padilla FJ; Martínez-Vázquez MA;
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(1):70-85. PubMed ID: 33317930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study.
    Ferretti F; Monico MC; Cannatelli R; Carmagnola S; Lenti MV; Di Sabatino A; Conforti F; Pastorelli L; Caprioli F; Bezzio C; Saibeni S; Mazza S; Vecchi M; Maconi G; Ardizzone S
    Front Med (Lausanne); 2022; 9():933357. PubMed ID: 36004370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
    Amiot A; Peyrin-Biroulet L
    Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES.
    Quaresma AB; Coy CSR; Damião AOMC; Kaplan GG; Kotze PG
    Arq Gastroenterol; 2019; 56(3):318-322. PubMed ID: 31633732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
    Card T; Ungaro R; Bhayat F; Blake A; Hantsbarger G; Travis S
    Aliment Pharmacol Ther; 2020 Jan; 51(1):149-157. PubMed ID: 31747086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDO
    di Giuseppe R; Plachta-Danielzik S; Mohl W; Hoffstadt M; Krause T; Bokemeyer B; Schreiber S
    Int J Colorectal Dis; 2021 Nov; 36(11):2445-2453. PubMed ID: 33963913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
    Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract]   [Full Text] [Related]  

  • 57. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
    Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
    Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
    Poullenot F; Amiot A; Nachury M; Viennot S; Altwegg R; Bouhnik Y; Abitbol V; Nancey S; Vuitton L; Peyrin-Biroulet L; Biron A; Fumery M; Picon L; Vidon M; Reenaers C; Serrero M; Savoye G; Beaugerie L; Rivière P; Laharie D
    J Crohns Colitis; 2022 Nov; 16(10):1523-1530. PubMed ID: 35512337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
    Nguyen GC; Harris ML; Dassopoulos T
    Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.